Pharmaceutical

Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome 

Harmony is advancing pitolisant into a Phase III clinical trial that is expected to start in Q1 2024.

Feb 22, 2024 - 18:00
Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome 
Harmony is advancing pitolisant into a Phase III clinical trial that is expected to start in Q1 2024.
Read the original article

Tags:

Previous Article

Immunocore and BMS partner to investigate first-line treatment for melanoma

Next Article

Immune-Onc’s antibody therapy collects second FDA orphan designation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: With biotech in a slump, the industry’s job market is upside down

STAT+: With biotech in a slump, the industry’s job mark...

Nov 27, 2023

STAT+: Radiology captures the tension between AI’s potential and concern for patients

STAT+: Radiology captures the tension between AI’s pote...

Dec 1, 2023

STAT+: Mirum’s Chenodal succeeds in late-stage trial for rare metabolic disorder

STAT+: Mirum’s Chenodal succeeds in late-stage trial fo...

Oct 2, 2023